NCT06690775 2025-12-23CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.TORL Biotherapeutics, LLCPhase 2 Recruiting230 enrolled
NCT05870748 2025-09-23REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1Sutro Biopharma, Inc.Phase 2/3 Terminated600 enrolled